

PHARMACY POLICY STATEMENT

Georgia Medicaid

DRUG NAME	Otezla, Otezla XR (apremilast)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Otezla, initially approved by the FDA in 2014, is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which Otezla exerts its therapeutic action is not well defined. A higher dose of Otezla is available as Otezla XR in a 75 mg tablet.

Otezla (apremilast) will be considered for coverage when the following criteria are met:

Oral Ulcers associated with Behçet’s Disease

For **initial** authorization:

1. Member is at least 18 years of age; AND
2. Medication must be prescribed by or in consult with a rheumatologist or dermatologist; AND
3. Member has a diagnosis of Behçet’s disease; AND
4. Member has recurrent oral ulcers with at least 2 active oral ulcers; AND
5. Member has had a trial and failure of a topical corticosteroid and/or colchicine.
6. **Dosage allowed/Quantity limit:** administer initial titration per package insert. Recommended maintenance dose is 30 mg twice daily or 75 mg once daily. Otezla quantity limit: 60 tablets per 30 days. Otezla XR quantity limit: 30 tablets per 30 days.

If all the above requirements are met, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes must show the member has experienced a decrease in the number of oral ulcers or decrease in pain level associated with oral ulcers.

If all the above requirements are met, the medication will be approved for an additional 12 months.

Psoriatic Arthritis (PsA)

For **initial** authorization:

1. Member is 6 years of age and older weighing at least 20 kg; AND
2. Medication must be prescribed by or in consultation with a rheumatologist or a dermatologist; AND
3. Member has a documented diagnosis of active psoriatic arthritis (PsA); AND
4. Member has met a 4-week trial of an NSAID taken at maximally tolerated dose AND a 3-month trial of a conventional DMARD agent (e.g., methotrexate, sulfasalazine, cyclosporine, etc.).
5. **Dosage allowed/Quantity limit:** administer initial titration per package insert. Otezla quantity limit: 60 tablets per 30 days. Otezla XR quantity limit: 30 tablets per 30 days.

- a) **Adults:** recommended maintenance dose is 30 mg twice daily or 75 mg once daily.
- b) **Pediatrics:**
 - i) 50 kg or more: administer maintenance dose of 30 mg twice daily or 75 mg once daily.
 - ii) 20 kg to less than 50 kg: administer maintenance dose of 20 mg twice daily.

If all the above requirements are met, the medication will be approved for 12 months.

For **reauthorization:**

1. Chart notes have been provided showing improvement of signs and symptoms of disease such as decreased joint swelling and pain, improved skin appearance, improved quality of life, etc.

If all the above requirements are met, the medication will be approved for an additional 12 months.

Plaque Psoriasis (PsO)

For **initial** authorization:

1. Member is between 6 and 17 years of age and weighs at least 20 kg; AND
2. Member has a documented diagnosis of moderate to severe plaque psoriasis, OR
3. Member is 18 years of age or older; AND
4. Member has a diagnosis of mild to severe plaque psoriasis; AND
5. Medication must be prescribed by or in consultation with a dermatologist; AND
6. Member has tried and failed to respond to treatment with at least **one** of the following:
 - a) At least 12 weeks of photochemotherapy (i.e., psoralen plus ultraviolet A therapy);
 - b) At least 12 weeks of phototherapy (i.e., UVB light therapy, Excimer laser treatments);
 - c) At least a 4-week trial with topical antipsoriatic agents (i.e., anthralin, calcipotriene, coal tar, corticosteroids, tazarotene, tacrolimus, pimecrolimus); AND
7. Member has tried and failed, or unable to tolerate a systemic conventional DMARD (i.e., cyclosporine, methotrexate, acitretin) for at least 12 weeks.
8. **Dosage allowed/Quantity limit:** administer initial titration per package insert. Otezla quantity limit: 60 tablets per 30 days. Otezla XR quantity limit: 30 tablets per 30 days
 - a) **Adults:** recommended maintenance dose is 30 mg twice daily or 75 mg once daily.
 - b) **Pediatrics:**
 - i) 50 kg or more: administer maintenance dose of 30 mg twice daily or 75 mg once daily.
 - ii) 20 kg to less than 50 kg: administer maintenance dose of 20 mg twice daily.

If all the above requirements are met, the medication will be approved for 12 months.

For **reauthorization:**

1. Chart notes have been provided showing improvement of signs and symptoms of disease such as documented member's BSA improvement, etc.

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Otezla (apremilast) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
05/10/2017	New policy for Otezla created. Policies SRx-0042 and SRx-0043 archived. For diagnosis of PsO: immunosuppressive criterion was separated from phototherapies and topical agents trials; TNF inhibitors Humira and Enbrel were listed as required trials; Psoriasis Area and Severity Index (PASI) score requirement was added. For diagnosis of PsA: TNF inhibitors Humira and Enbrel were listed as required trials. List of diagnoses considered not medically necessary was added.
02/26/2019	Status changed to preferred. Humira and Enbrel trials removed from criteria. Clarifications entered for AS and PsA on NSAIDs trial length. Requirements on axial disease type removed from PsA. Physician Global Assessment score removed from diagnosis of PsO. References added. Reauthorization criteria on documented member's PASI score improvement incorporated into general chart noted documentation requirements.
07/28/2019	New diagnosis of Oral Ulcers Associated With Behçet's Disease added.
11/23/2020	Replaced list of excluded diagnoses with the generic statement. Updated references. PsA: Added requirement of diagnosis of PsA. Removed non-axial disease requirement. Specified trials to be 4 weeks of an NSAID AND 3 months of a DMARD. PsO: Removed rheumatologist from prescriber. Changed BSA to 3% or sensitive area involvement. Removed PASI score requirement.
02/03/2021	Behçet's disease: Updated references. Changed initial approval duration from 12 months to 6 months. Specified they must have active ulcers. Changed the step drugs to match EULAR guideline recommendations. Made the renewal criteria specific.
02/23/2022	Transferred to new template. PSO: Removed "moderate to severe" per label change. Clarified reauthorization criteria for PsA.
05/22/2024	Simplified adult dosing; added references. PsO: added pediatric dosing and quantity limit; specifying those 18 years of age and greater must have a diagnosis of mild to severe disease and those between 6 years of age and 17 years of age and greater than 20 kg must have a diagnosis of moderate to severe disease.
09/15/2025	Added references. Added Otezla XR to policy including separate QL. Removed dosing tables, replaced with refer to PI. Changed "non-biologic DMARD" to "conventional DMARD." PsO: changed Otezla quantity limit from 30 tablets per 30 days to 60 tablets per 30 days. PsA: lowered age limit from 18 to 6 years of age and added greater than 20 kg

References:

- Otezla [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2025.
- Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. *Nat Rev Rheumatol*. 2022;18(8):465-479. doi:10.1038/s41584-022-00798-0
- Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. *Ann Rheum Dis*. 2024;83(6):706-719. Published 2024 May 15. doi:10.1136/ard-2024-225531
- Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures [published online ahead of print, 2020 Jul 30]. *J Am Acad Dermatol*. 2020;S0190-9622(20)32288-X.
- Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol*. 2020;82(6):1445-1486.

6. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072.
7. Elmetts CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy [published correction appears in *J Am Acad Dermatol*. 2020 Mar;82(3):780]. *J Am Acad Dermatol*. 2019;81(3):775-804.
8. Menter A, Cordoro KM, Davis DM, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis in pediatric patients. *J Am Acad Dermatol* 2020;82:161-201.
9. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. *Ann Rheum Dis*. 2018;77(6):808-818. doi:10.1136/annrheumdis-2018-213225
10. Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. *N Engl J Med*. 2019;381(20):1918-1928. doi:10.1056/NEJMoa1816594
11. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients [published correction appears in *J Am Acad Dermatol*. 2020 Mar;82(3):574]. *J Am Acad Dermatol*. 2020;82(1):161-201. doi:10.1016/j.jaad.2019.08.049
12. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of Psoriatic Arthritis. *Arthritis Rheumatol*. 2019 Jan;71(1):5-32.

Effective date: 05/01/2026

Revised date: 09/15/2025